Recently, BIOKANGTAI's wholly-owned subsidiary, Beijing Minhai Biotechnology, has signed a sales contract with its Indonesian partner, in which a detailed agreement was made on the quantity, unit price, total amount of the order, and shipment date of the world's first dual-carrier 13-valent pneumococcal conjugate vaccine developed and produced by BIOKANGTAI to be exported to Indonesia.

In October 2023, Minhai Biotech obtained the Marketing License for 13-valent Pneumococcal Polysaccharide Conjugate Vaccine issued by the Indonesian Food and Drug Administration, marking that the vaccine has the basic conditions for sale in the local market in Indonesia. The signing of this contract indicates that after years of market expansion, Kangtai's 13-valent pneumococcal vaccine has formally opened for overseas sales, and as the relevant work continues to progress, this variety will bring new growth points for the company's 2024 annual results.

Dr. Lucia Rizka Andalusia, Acting Head of Indonesia's Food and Drug Regulatory Agency (BIOKANGTAI) and Director General of Pharmaceuticals and Medical Devices, led a team to investigate BIOKANGTAI's Guangming Base in Shenzhen. She highly praised BIOKANGTAI's advanced technological facilities, solid R&D background, and rigorous quality system, and fully affirmed a series of progresses BIOKANGTAI and its Indonesian partners have made so far. She said that the 13-valent pneumonia vaccine has been included in the immunization program in some key areas of Indonesia since 2022, and the nationwide supply of the vaccine will be gradually expanded in the future. She also hoped that BIOKANGTAI, with its unique advantages in the field of technology such as multi-linked polyvalent vaccine, will deeply cooperate with local pharmaceutical companies in Indonesia to bring more advanced, effective and safe vaccine varieties to Indonesia for the benefit of more people's health.

https://mp.weixin.qq.com/s/mvrUrpjWwBptH8A6yn-NJw